First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...
STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...
Zacks Investment Research on MSN
Pharma, biotech giants ramp up M&A in Q1 to boost pipelines
Mergers and acquisitions (M&A) in the pharma and biotech sector have accelerated notably year to date, building on a rebound in 2025. A recent surge in dealmaking underscores the industry’s focus on ...
Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline. The Marseille-headquartered company had been ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali Therapeutics. The California biotech took ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results